BLRX Inventory Forecast 2025
The BLRX inventory forecast for 2025 is a prediction of the long run worth of BioXcel Therapeutics’ inventory. BioXcel Therapeutics is a clinical-stage biopharmaceutical firm growing novel remedies for neuropsychiatric problems. The corporate’s lead product candidate, BXCL501, is a Part 3-ready, investigational, oral treatment for the remedy of agitation in sufferers with Alzheimer’s illness.
